Drug Profile
Research programme: pain therapeutics - Jubilant Biosys/Orion Corporation
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Jubilant Biosys; Orion
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Pain in India
- 28 Jun 2018 No recent reports of development identified for research development in Pain in USA
- 13 May 2014 Early research in Pain in USA and India (unspecified route)